The strong Phase 1 data and accelerated development of PLN-101095 represent a significant value inflection point. The extended cash runway reduces near-term dilution risk. Traders should monitor upcoming interim data from the Phase 1b trial in 2027 as a key catalyst.
Price Chart
Executive Summary
Pliant Therapeutics reported fourth quarter 2025 financial results and provided a corporate update, highlighting positive Phase 1 data for its oncology drug PLN-101095 in checkpoint inhibitor-refractory solid tumors. The company initiated a Phase 1b indication expansion trial and reported reduced R&D and G&A expenses, leading to a narrower net loss. It has $192.4 million in cash, sufficient to fund operations into the second half of 2028.
Key Financial Metrics
Key Facts
- PLN-101095 showed deep and durable responses in ICI-refractory patients, with 4 responders (1 complete, 3 partial) out of 10 patients across multiple tumor types.
- Phase 1b indication expansion trial initiated in NSCLC, renal cell carcinoma, and high tumor mutational burden tumors, with first patient enrollment expected in Q2 2026 and interim data in 2027.
- Q4 2025 R&D expenses decreased to $15.6M from $38.8M YoY due to discontinuation of BEACON-IPF.
- Q4 2025 G&A expenses decreased to $8.0M from $14.5M YoY due to workforce restructuring.
- Net loss narrowed to $23.6M from $49.7M YoY.
- Cash, cash equivalents, and short-term investments totaled $192.4M as of December 31, 2025, expected to fund operations into H2 2028.
Financial Impact
R&D expenses down 60% YoY, G&A down 45% YoY, net loss down 52.5% YoY, with cash runway extending into 2028.
Risk Factors
- Clinical development risk: PLN-101095 is still in early stages; future trial results may not replicate initial success.
- Dilution risk: Despite current cash runway, future financing may be required for later-stage trials, potentially diluting shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001746473-26-000039 |
| Document: plrx-20260311.htm | 0001746473-26-000039 |
| Document: 0001746473-26-000039-index-headers.html | 0001746473-26-000039 |
| Document: 0001746473-26-000039-index.html | 0001746473-26-000039 |
| Document: 0001746473-26-000039.txt | 0001746473-26-000039 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 6w ago | Press Release | $1.15 $1.15 | ▼ −0.43% | ▲ +0.55% | $1.03 (−10.43%) |
May 11, 2026 20w ago | 8-K | $1.18 $1.16 | ▼ −1.69% | ▲ +0.03% | $1.03 (−12.71%) |
May 11, 2026 20w ago | Press Release | $1.18 $1.16 | ▲ +1.69% | ▼ −0.03% | $1.03 (+12.71%) |
Apr 17, 2026 23w ago | 8-K | $1.29 $1.18 | ▼ −8.53% | ▼ −12.73% | $1.03 (−20.16%) |
Apr 7, 2026 25w ago | EFFECT | $1.31 $1.19 | ▼ −9.16% | ▼ −18.94% | $1.03 (−21.37%) |
Mar 11, 2026 29w ago | 8-K | $1.41 $1.28 | ▼ −9.22% | ▼ −11.19% | $1.03 (−26.95%) |
Mar 3, 2026 30w ago | 8-K | $1.29 $1.32 | ▲ +2.33% | ▲ +6.74% | $1.03 (−20.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access